Fenobam

(HB0286)

Product overview

  • Name
    Fenobam
  • Short description
    Potent, selective, non-competitive mGlu5 antagonist
  • Biological description
    Potent, selective and non-competitive mGlu5 receptor antagonist. Acts at allosteric modulatory site (Kd values are 54 and 31 nM at rat and human mGlu5 receptors respectively). Shows inverse agonist properties on receptor basal activity (IC50 value = 84 nM). Displays analgesic, anxiolytic and antidepressant effects. Orally active.
  • Biological action
    Antagonist
  • Purity
    >99%
  • Citations

Properties

  • Chemical name
    N-(3-Chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazol-2-yl)urea
  • Molecular Weight
    266.69
  • Chemical structure
    Fenobam  [57653-26-6]
  • Molecular Formula
    C11H11N4O2Cl
  • CAS Number
    57653-26-6
  • PubChem identifier
    162834
  • SMILES
    CN1CC(=O)N=C1NC(=O)NC2=CC(=CC=C2)Cl
  • Source
    Synthetic
  • InChi
    InChI=1S/C11H11ClN4O2/c1-16-6-9(17)14-10(16)15-11(18)13-8-4-2-3-7(12)5-8/h2-5H,6H2,1H3,(H2,13,14,15,17,18)
  • InChiKey
    DWPQODZAOSWNHB-UHFFFAOYSA-N
  • MDL number
    MFCD00868019
  • Appearance
    Yellow solid

Storing and Using Your Product

  • Storage instructions
    Room temperature
  • Solubility overview
    Soluble in DMSO (100mM)
  • Important
    This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

References for Fenobam

  • Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity.

    Porter RH et al (2005) J Pharmacol Exp Ther 315(2) : 711-21.
    PubMedID: 16040814
  • Antagonists at metabotropic glutamate receptor subtype 5: structure activity relationships and therapeutic potential for addiction.

    Carroll FI (2008) Ann N Y Acad Sci 1141 : 221-32.
    PubMedID: 18991960
  • The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in vivo selectivity compared with the prototypical antagonist 2-methyl-6-(phenylethynyl)-pyridine.

    Montana MC et al (2009) J Pharmacol Exp Ther 330(3) : 834-43.
    PubMedID: 19515968